Skip to Content

Stage 1 Core Measure 2

Next Measure Previous Measure


Measure at a Glance

Type: enabled function

Denominator: none

Duration: enabled during the entire EHR reporting period

Objective: Implement drug-drug and drug-allergy interaction checks.
Measure: The EP has enabled this functionality for the entire EHR reporting period.
Exclusion: No exclusion.
There are no changes to this objective and measure regardless of when EPs attest to Stage 1 Meaningful Use.

CMS Technical Specification

TennCare Notes
The attestation portal will require the EP to choose yes or no to having enabled this functionality.

Relevant CMS FAQs

  • 10077: clarifying non-applicability to clinical decision support rule

Additional Resources
None at this time.

Federal Regulations Governing This Measure

CMS' Final Rule

§ 495.6(d)(2) see objective and measure above

Standards and Certification Final Rule

§ 170.304(a) Drug-drug, drug-allergy interaction checks

  1. Notifications. Automatically and electronically generate and indicate in real-time, notifications at the point of care for drug-drug and drug-allergy contraindications based on medication list, medication allergy list, and computerized provider order entry (CPOE).
  2. Adjustments. Provide certain users with the ability to adjust notifications provided for drug-drug and drug-allergy interaction checks.